Payment overview · 2025
General Payments
$545.88
31 reported records · 13 companies
Healthcare provider profile · identity verified
Shodhan Patel, MD
Allopathic & Osteopathic Physicians|Internal Medicine · TRENTON, NJ · NPI 1457368680
Verified facts
What the public records show
CMS Open Payments records show Shodhan Patel, MD received $545.88 in general payments during 2025 across 31 reported records.
Novo Nordisk Inc accounted for 17.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 235 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Arexvy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 235 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 498 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $96.37 | 17.6% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $83.74 | 15.3% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $70.35 | 12.9% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $44.92 | 8.2% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $44.00 | 8.1% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $39.52 | 7.2% | 2 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $37.95 | 7.0% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $36.48 | 6.7% | 2 | 2025 |
| Avadel CNS Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $29.66 | 5.4% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $18.39 | 3.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.85 | 3.1% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.94 | 2.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.71 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $545.88 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $69.95 | 4 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $69.95 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $69.95 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $63.12 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $44.92 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $44.92 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $44.00 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $43.46 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $39.52 | 2 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $37.95 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $33.25 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $33.25 | 2 | 2025 |
Source payment records
|
|||||
| LUMRYZ Normalized: lumryz |
Drug | Avadel CNS Pharmaceuticals, LLC | $29.66 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $26.89 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $18.63 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $18.39 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $17.85 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.85 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $13.94 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $13.79 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $13.79 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $13.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 137 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 235 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 123 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
137 | 24 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
235 | 27 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
235 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
123 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
498 | 42 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1256 | 209 |
| Amlodipine Besylate | Amlodipine Besylate | 1060 | 205 |
| Gabapentin | Gabapentin | 689 | 92 |
| Eliquis | Apixaban | 498 | 42 |
| Metformin Hcl | Metformin Hcl | 484 | 101 |
| Metoprolol Succinate | Metoprolol Succinate | 471 | 86 |
| Levothyroxine Sodium | Levothyroxine Sodium | 403 | 73 |
| Pantoprazole Sodium | Pantoprazole Sodium | 371 | 79 |
| Tamsulosin Hcl | Tamsulosin Hcl | 347 | 50 |
| Carvedilol | Carvedilol | 320 | 53 |
| Clopidogrel | Clopidogrel Bisulfate | 295 | 41 |
| Furosemide | Furosemide | 284 | 60 |
| Trazodone Hcl | Trazodone Hcl | 262 | 34 |
| Mirtazapine | Mirtazapine | 256 | 29 |
| Valsartan | Valsartan | 245 | 54 |
| Jardiance | Empagliflozin | 235 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 217 | 35 |
| Quetiapine Fumarate | Quetiapine Fumarate | 202 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 185 | 50 |
| Metoprolol Tartrate | Metoprolol Tartrate | 183 | 28 |
| Baclofen | Baclofen | 175 | 19 |
| Simvastatin | Simvastatin | 173 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 169 | 40 |
| Lisinopril | Lisinopril | 167 | 37 |
| Sertraline Hcl | Sertraline Hcl | 162 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 161 | 47 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 159 | 26 |
| Losartan Potassium | Losartan Potassium | 157 | 34 |
| Potassium Chloride | Potassium Chloride | 156 | 30 |
| Citalopram Hbr | Citalopram Hydrobromide | 140 | 12 |
| Farxiga | Dapagliflozin Propanediol | 137 | 24 |
| Omeprazole | Omeprazole | 136 | 29 |
| Alprazolam | Alprazolam | 135 | 32 |
| Januvia | Sitagliptin Phosphate | 135 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 134 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 123 | 24 |
| Ozempic | Semaglutide | 123 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 120 | 25 |
| Azelastine Hcl | Azelastine Hcl | 112 | 44 |
| Donepezil Hcl | Donepezil Hcl | 111 | 20 |
| Montelukast Sodium | Montelukast Sodium | 108 | 19 |
| Tradjenta | Linagliptin | 107 | suppressed |
| Glipizide | Glipizide | 102 | 17 |
| Latanoprost | Latanoprost | 102 | 18 |
| Levetiracetam | Levetiracetam | 101 | 13 |
| Risperidone | Risperidone | 101 | suppressed |
| Famotidine | Famotidine | 98 | 21 |
| Allopurinol | Allopurinol | 94 | 17 |
| Ezetimibe | Ezetimibe | 92 | 18 |
| Finasteride | Finasteride | 90 | 15 |
| Nifedipine Er | Nifedipine | 81 | 17 |
| Ipratropium Bromide | Ipratropium Bromide | 79 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 77 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 76 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 71 | 12 |
| Enalapril Maleate | Enalapril Maleate | 71 | 13 |
| Linzess | Linaclotide | 71 | 18 |
| Meloxicam | Meloxicam | 71 | 20 |
| Xarelto | Rivaroxaban | 71 | suppressed |
| Azithromycin | Azithromycin | 69 | 55 |
| Fluoxetine Hcl | Fluoxetine Hcl | 69 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 69 | suppressed |
| Entresto | Sacubitril/Valsartan | 68 | suppressed |
| Olanzapine | Olanzapine | 68 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 68 | suppressed |
| Prednisone | Prednisone | 67 | 25 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 67 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 66 | 13 |
| Celecoxib | Celecoxib | 65 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 65 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 64 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 62 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 61 | 24 |
| Divalproex Sodium | Divalproex Sodium | 61 | suppressed |
| Clonazepam | Clonazepam | 60 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 58 | 14 |
| Midodrine Hcl | Midodrine Hcl | 58 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 55 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 54 | 14 |
| Myrbetriq | Mirabegron | 54 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 53 | suppressed |
| Memantine Hcl | Memantine Hcl | 53 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 52 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 51 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 51 | suppressed |
| Lorazepam | Lorazepam | 50 | 11 |
| Acarbose | Acarbose | 48 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 47 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 46 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | 14 |
| Clonidine Hcl | Clonidine Hcl | 45 | suppressed |
| Digoxin | Digoxin | 45 | suppressed |
| Irbesartan | Irbesartan | 45 | suppressed |
| Torsemide | Torsemide | 44 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 43 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 43 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 42 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 42 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 41 | 11 |
| Haloperidol | Haloperidol | 41 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 41 | 12 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 39 | suppressed |
| Ketoconazole | Ketoconazole | 38 | 17 |
| Insulin Lispro | Insulin Lispro | 37 | 14 |
| Scopolamine | Scopolamine | 37 | suppressed |
| Spironolactone | Spironolactone | 37 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 37 | 18 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 36 | 16 |
| Lacosamide | Lacosamide | 36 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 36 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 29 |
| Aripiprazole | Aripiprazole | 34 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 34 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 34 | suppressed |
| Telmisartan | Telmisartan | 34 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 34 | 13 |
| Cinacalcet Hcl | Cinacalcet Hcl | 33 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 33 | suppressed |
| Lubiprostone | Lubiprostone | 33 | suppressed |
| Vascepa | Icosapent Ethyl | 33 | suppressed |
| Bicalutamide | Bicalutamide | 32 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 32 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 31 | suppressed |
| Steglatro | Ertugliflozin Pidolate | 31 | suppressed |
| Trulicity | Dulaglutide | 31 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 31 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Dorzolamide-Timolol | Dorzolamide/Timolol/Pf | 30 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 29 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 28 | suppressed |
| Anastrozole | Anastrozole | 27 | suppressed |
| Bumetanide | Bumetanide | 27 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 27 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | suppressed |
| Pregabalin | Pregabalin | 27 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Liraglutide | Liraglutide | 26 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 26 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 25 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 25 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 25 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 24 | 14 |
| Cefuroxime | Cefuroxime Axetil | 24 | 21 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 24 | suppressed |
| Ranolazine Er | Ranolazine | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 23 | suppressed |
| Gemtesa | Vibegron | 23 | suppressed |
| Mounjaro | Tirzepatide | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 21 | suppressed |
| Phenytoin | Phenytoin | 21 | suppressed |
| Procrit | Epoetin Alfa | 21 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 21 | suppressed |
| Enbrel | Etanercept | 20 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 20 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 19 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 19 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Acitretin | Acitretin | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 14 |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 14 |
| Nystatin | Nystatin | 17 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 17 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 16 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Cephalexin | Cephalexin | 16 | 15 |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Repaglinide | Repaglinide | 16 | suppressed |
| Valproic Acid | Valproic Acid | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 15 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Oxycontin | Oxycodone Hcl | 15 | suppressed |
| Paliperidone Er | Paliperidone | 15 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 15 | suppressed |
| Timolol Maleate | Timolol Maleate | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | suppressed |
| Nyamyc | Nystatin | 14 | suppressed |
| Paricalcitol | Paricalcitol | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 13 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 12 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 13 | suppressed |
| Belbuca | Buprenorphine Hcl | 12 | suppressed |
| Desloratadine | Desloratadine | 12 | suppressed |
| Dulera | Mometasone/Formoterol | 12 | suppressed |
| Eplerenone | Eplerenone | 12 | suppressed |
| Methylprednisolone Acetate | Methylprednisolone Acetate | 12 | suppressed |
| Perphenazine | Perphenazine | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Alphagan P | Brimonidine Tartrate | 11 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $545.88 · 31 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, AUSTEDO XR, BEXSERO, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, FARXIGA, GVOKE HYPOPEN, JARDIANCE, LUMRYZ, MOUNJARO, NURTEC ODT, Ozempic, PREVNAR 20, Rybelsus, TRELEGY ELLIPTA, VOQUEZNA, Wegovy, XYWAV, ZAVZPRET, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error